Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells ; volume:9 ; number:1 ; day:14 ; month:3 ; year:2019 ; pages:1-7 ; date:12.2019
Scientific reports ; 9, Heft 1 (14.3.2019), 1-7, 12.2019

Classification: Naturwissenschaften

Creator: Lian, Shu
Xie, Ruizhi
Ye, Yuying
Lu, Yusheng
Cheng, Yunlong
Xie, Xiaodong
Li, Shuhui
Jia, Lee

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-019-40241-1

URN: urn:nbn:de:101:1-2019040319533624305100

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lian, Shu
Xie, Ruizhi
Ye, Yuying
Lu, Yusheng
Cheng, Yunlong
Xie, Xiaodong
Li, Shuhui
Jia, Lee
SpringerLink (Online service)

Other Objects (12)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

PD-L1 degradation pathway and immunotherapy for cancer

Targeting CD47 for cancer immunotherapy

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Hochschulschrift

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

PD-L1 degradation pathway and immunotherapy for cancer

Targeting CD47 for cancer immunotherapy

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Hochschulschrift

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

PD-L1 degradation pathway and immunotherapy for cancer

Targeting CD47 for cancer immunotherapy

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Hochschulschrift

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

PD-L1 degradation pathway and immunotherapy for cancer

Targeting CD47 for cancer immunotherapy

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

PD-L1 degradation pathway and immunotherapy for cancer

Targeting CD47 for cancer immunotherapy

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

PD-L1 degradation pathway and immunotherapy for cancer

Targeting CD47 for cancer immunotherapy

Clinical applications of PD-L1 bioassays for cancer immunotherapy

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

The role of exosomal PD-L1 in tumor progression and immunotherapy

Related objects

Reset password